HES – Patient Worthy

FASENRA Demonstrates Breakthrough Results in Rare Eosinophilic Disease: NATRON Trial Shows Promise for Hypereosinophilic Syndrome Patients

Post author:Bree Clare
Post published:November 24, 2025
Post category:Hypereosinophilic syndrome

Hypereosinophilic syndrome (HES) patients may finally have a meaningful treatment option. According to an article published at BusinessWire.com, AstraZeneca's FASENRA (benralizumab) has shown statistically significant efficacy in delaying disease progression,…

stevepb / Pixabay

Nucala Recommended for Three New Indications

Post author:Kendall Mason
Post published:September 27, 2021
Post category:Eosinophilic asthma Eosinophilic granulomatosis with polyangiitis Hypereosinophilic syndrome nasal polyposis

Nucala has already been approved in Europe as an add-on treatment for patients with extreme eosinophilic asthma. Now, the EMA's Committee for Medicinal Products for Human Use (CHMP) has recommended…

source: pixabay.com

Hypereosinophilic Syndrome Has First FDA Approved Therapy in 14 Years

Post author:Sunniva Bean
Post published:October 12, 2020
Post category:Hypereosinophilic syndrome

This week, the US FDA announced that they approved the drug Nucala (mepolizumab) to treat patients with hypereosinophilic syndrome, a rare chronic blood disease which causes organ damage. Nucala is…

source: pixabay.com

Nucala (Mepolizumab) Approved as HES Treatment

Post author:Jessica Lynn
Post published:October 9, 2020
Post category:Hypereosinophilic syndrome

In late September, GlaxoSmithKline announced FDA approval of its treatment, Nucala, for patients with hypereosinophilic syndrome (HES). The treatment is safe for patients older than 12. Additionally, this approval is…

source: pixabay.com

Nucala Granted Priority Review as Possible Biologic Treatment For HES

Post author:Sunniva Bean
Post published:June 9, 2020
Post category:Hypereosinophilic syndrome

As reported in GSK, the FDA has just granted priority review to Nucala (mepolizumab), a targeted biological treatment to help patients with hypereosinophilic syndrome (HES). If the medication is accepted,…

Orphan Drug Designation Given to New Potential Oral Therapy for Hypereosinophilic Syndrome

Post author:Trudy Horsting
Post published:April 26, 2019
Post category:Hypereosinophilic syndrome

Hypereosinophilic Syndrome Hypereosinophilic syndrome (HES) is a rare disease which causes high levels of white blood cells in the body. These cells are called eosinophils, and they're essential for proper…

Orphan Drug Designation Granted to Potential New Hypereosinophilic Syndrome Treatment

Post author:Trudy Horsting
Post published:February 11, 2019
Post category:Hypereosinophilic syndrome Nasal polyposis, familial

Hypereosinophilic syndrome Hypereosinophilic syndrome (HES) refers to a group of rare conditions characterized by high levels of eosinophils which result in organ damage. These eosinophils often affect the lungs, heart, skin,…

fill / Pixabay

Know All About It! Register for Hypereosinophilic Syndrome Conference in March 2018

Post author:Chloe Easterbrook
Post published:November 24, 2017
Post category:Event Hypereosinophilic syndrome Rare Disease

No one knows how difficult living with hypereosinophilic syndrome (HES) is unless you walk in the shoes of those who have it, treat it, or have a loved one who…

FASENRA Demonstrates Breakthrough Results in Rare Eosinophilic Disease: NATRON Trial Shows Promise for Hypereosinophilic Syndrome Patients

Nucala Recommended for Three New Indications

Hypereosinophilic Syndrome Has First FDA Approved Therapy in 14 Years

Nucala (Mepolizumab) Approved as HES Treatment

Nucala Granted Priority Review as Possible Biologic Treatment For HES

Orphan Drug Designation Given to New Potential Oral Therapy for Hypereosinophilic Syndrome

Orphan Drug Designation Granted to Potential New Hypereosinophilic Syndrome Treatment

Know All About It! Register for Hypereosinophilic Syndrome Conference in March 2018

Let’s Work Together!

Keep Up to Date

Learn More